非小细胞肺癌靶向治疗回顾与进展-现代医学

非小细胞肺癌靶向治疗回顾与进展

单位：东南大学医学院, 江苏南京 210009

分类号：R734.2

出版年·卷·期（页码）：2018·46·第二期（229-234）

摘要：

非小细胞肺癌（NSCLC）发病率高，发现困难，治疗效果差。放疗及化疗近年来无历史性突破，靶向药物以其独特的优势，在非小细胞肺癌的治疗中占据重要地位。靶向治疗是针对肿瘤细胞及其生长微环境，使用相应的阻滞剂抑制肿瘤的生长与增殖。近年来，新的靶点和新的靶向药物不断出现。本文回顾及展望非小细胞肺癌靶向治疗的研究。本文主要从以下几个方面阐述：一、概括对已知靶点的介绍；二、结合文献中的研究数据，概括靶向药物的临床研究；三、靶向药物的耐药情况及解决方法。

The morbidity of Non-small cell lung cancer(NSCLC) is high and has difficulty in its diagnosis and treatment. Radiotherapy and chemotherapy for NSCLC did not havea historic breakthrough in recent years. Targeted therapy is directly against tumor cell and their growth microenvironment, using the corresponding blockers to inhibit tumor growth and proliferation. Targeting drugs played an important role with its unique advantages in the treatment of NSCLC. In recent years, new targets and new targeting drugs have been emerging. This paper reviews and prospects the research on targeted therapy for NSCLC and mainly elaborates from the following aspects:to summarize and introduce the known targets; to summarize the clinical research of targeting drugs combined with the literature research data; to introduce the drug resistance and the solution for it.

参考文献：

[1] LI X S,XIA F.Research progress of molecular-targeted agents in hepato-cellular carcinoma[J].Chin J Pract Surg,2014,34(8):786-789.
[2] PAEZ J G,JAMES P A,LEE J C,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib-therapy[J].Science,2004,304(5676):1497-1500.
[3] LYNCH T J,BELL D W,SORDELLA R,et al.Activating mutations in the epidemal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
[4] PAO W,MILLER V,ZAKOWSKI M,et al.EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101(36):13306-13311.
[5] TOKUMO M,TOYOOKA S,KIURA K,et al.The relationship between epidermal growth factor recepter mutations and clinicopathologic features in non-small-cell lung cancers[J].Clin Cancer Res,2005,11(3):1167-1173.
[6] HOLMES K,ROBERTS O L,THOMAS A M,CROSS M J.Vascular endothelial growth factor receptor-2:structure,function,intracellular signalling and therapeutic inhibition[J].Cell Signal,2007,19(10):2003-2012.
[7] JIA Y,JUAREZ J,LI J,et al.EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor[J].Cancer Res.2016.76(6):1591-1602.
[8] GAZDAR A F.EGFR mutations in lung cancer:Different frequencies for different folks[J].J Thorac Oncol,2014,9(2):139-140.
[9] DMOLLBERG N,SURATUI M,DEMCHUK C,et al.Mind mapping for lung cancer:towards a personalized therapeutics approach[J].Adv Ther,2011,28(3):173-194.
[10] FUKUOKA M,YANO S,GIACCONE G,et,al.Multiinstitutiomal randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non small cell lung cancer(The IDEAL 1 Trial)[J].J Clin Oncol,2003,21(12):2237-2246.
[11] MOK T S,WU Y L, THONGORASERT S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361():947-957.
[12] SHEPHERD F A,RODRIGUES PEREIRA J,CIULEANU T,et al.Erlotinib in previously treated non samll cell lung cancer[J].N Engl J Med,2005,353(2):123-132.
[13] ROSELL R,CARCERENY E,GERVAIS R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-lable,randomised phase 3 trial[J].Lancet Oncol,2012,13(3):239-246.
[14] ZHOU C,WU Y L,CHEN G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL,CTONG-0802):a muiticentre,open-lable,randomised,phase 3 study[J].Lanced Oncol,2011,12(8):735-742.
[15] YANG J C,HIRSH V,SCHULER M,et al.Symptom control and quality of life in LUX-Lung 3:a phase Ⅲ study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations[J].J Clin Oncol,2013,31(27):3342-3350.
[16] JACKMAN D,PAO W,RIELY G J,et al.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non small cell lung cancer[J].J Clin Oncol,2010,28(2):357-360.
[17] SEQUIST L V,WALTMAN B A,Dias-Santagata D,et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J].Sci Transl Med,2011,3(75):75ra26.
[18] KIM I H,LEE I H,LEE J E,et al.Prognostic impact of multiple clinicopathologic risk factors and c-MET overexpression in patients Who have undergone resection of stage IB non-small-cell lung cancer[J].Clin Lung Cancer,2016,17(5):e31-e43.
[19] CREQUIT P,RUPPERT A M,ROZENSZTAJN N,et al.EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients[J].Lung Cancer.2016.96:74-77.
[20] BU S,WANG R,PAN Y,et al.Clinicopathologic characteristics of patients with HER2 insertions in non-small cell lung cancer[J].Ann Surg Oncol,2017,24(1):291-297.
[21] NGUYEN K S,KOBAYASHI S,COSTA D B.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway[J].Clin Lung Cancer,2009,10(4):281-289.
[22] KWAK E L,SORDELLA R,BELL D W,et al.Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J].Proc Natl Acad Sci USA,2005,102(8):7665-7670.
[23] KAWK E L,BANG Y J,CAMIDGE D R,et al.Anaplastic lymphoma kinase inhibition in non small cell lung cancer[J].N Engl J Med,2010,363(18):1693-1703.
[24] SODA M,CHOI Y L,ENOMOTO M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561-566.
[25] WU J,SAVOOJI J,LIU D.Second-and third-generation ALK inhibitors for non-small cell lung cancer[J].Hematol Oncol,2016,9():19.
[26] SOLOMON B J,MOK T,KIM D W,et al.First line crizotinib versus chemotherapy in ALK-position lung cancer[J].N Engl J Med,2014,371(23):2167-2177.
[27] CAMIDGE DR,BANG Y J,KWAK E L,et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer:updated results from a phase 1 study[J].Lancet Ancol,2012,13(10):1011-1019.
[28] FRAMPTON J E.Crizotinib:a review of its use in the treatment of anaplastic lymphoma kinase-positive,advanced non-small cell lung cancer[J].Drugs,2013,73(18):2031-2051.
[29] 蒋涛,周彩存.ALK阳性非小细胞肺癌患者克唑替尼耐药的机制和治疗措施[J].中国肺癌杂志,2015,18(2):69-74.
[30] MATIKAS A,KENTEPOZIDIS N,GEORGOULIAS V,et al.Management of resistance to crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer[J].Clin Lung Cancer,2016,17(6):474-482.
[31] KIM D W,MEHRA R,TAN D S,et al.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer(ASCEND-1):updated results from the multicentre,open-label,phase 1 trial[J].Lancet Oncol.2016.17(4):452-463.
[32] ROSELL R,GETTINGER S N,BAZHENOVA L A,et al.1330:Brigatinib efficacy and safety in patients(Pts) with anaplastic lymphoma kinase(ALK)-positive(ALK+) non-small cell lung cancer(NSCLC) in a phase 1/2 trial[J].Thorac Oncol,2016,11(4 Suppl):S114.
[33] PRADEEP C R,SUNILA E S,KUTTAN G.Expression of vascular endothelial growth factor(VEGF) and VEGF receptors in tumor angiogenesis and malignancies[J].Integr Cancer Ther,2005,4(4):315-321.
[34] FERRARA N.VEGF and the quest for tumor angiogenesis factors[J].Nat Rev Cancer,2002,2(10):795-803.
[35] FERRARA N,GERBER H P,LECOUTER J.The biology of-VEGF-and-its-receptors[J].Nat-Med,2003,9(6):669-676.
[36] LANGER C,SORIA JC.The role of anti-epidemal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non small cell lung cancer[J].Clin Lung Cancer,2010,11(2):82-90.
[37] JOHNSON D H,FEHRENBACHER L,NOVOTNY W F,et al.Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J].Clin Oncol,2004,22(11):2184-2191.
[38] SANDLER A,GRAY R,PERRY M C,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355(24):2542-2550.
[39] HERBST R S,O'NEILL V J,FEHRENBACHER L,et al.Phase Ⅱ study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer[J].Clin Oncol,2007,25(30):4743-4750.
[40] RECK M,VON PAWEL J,ZATLOUKAL P,et al.Overall survival with cisplatin gemcitabine and bevacizumab or placebo as first-line therapy for non squamous non-small-cell lung cancer:results from a randomized phase Ⅲ trail(AVAIL)[J].Ann Oncol,2010,21(9):1804-1809.
[41] GARON E B,CIULEANU T E,ARRIETA O,et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage Ⅳ non-small-cell lung cancer after disease progression on platinum-based therapy(REVEL):a multicentre,double-blind,randomised phase 3 trial[J].Lancet,2014,384(9944):665-673.
[42] RAMALINGAM S,YANG J C,LEE C K,et al.LBA1_PR:Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC:updated efficacy and safety results from two Phase I expansion cohorts[J].Thorac Oncol,2016,11(4 Suppl):S152.
[43] VAN DER STEEN N,GIOVANNETTI E,PAUWELS P,et al.cMET Exon 14 skipping:from the structure to the clinic[J].Thorac Oncol,2016,11(9):1423-1432.
[44] PAIK P K,DRILON A,FAN P D,et al.Response to MET inhibitors in patients with stage Ⅳ lung adenocarcinomas harboring MET mutations causing exon 14 skipping[J].Cancer Discov,2015,5(8):842-849.
[45] JANNE P A,SHAW A T,PEREIRA J R,et al.Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer:a randomised,multicentre,placebo-controlled,phase 2 study[J].Lancet Oncol,2013,14():38-47.
[46] SHAW A T,OU S H,BANG Y J,et al.Crizotinib in ROS1-rearranged non-small-cell lung cancer[J].N Engl J Med,2014,371(21):1963-1971.
[47] MAZIERES J,ZALCMAN G,CRINO L,et al.Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement:results from the EUROS1 cohort[J].Clin Oncol,201533():992-999.
[48] MAZIERES J,PETERS S,LEPAGE B,et al.Lung cancer that harbors an HER2 mutation:epidemiologic characteristics and therapeutic perspectives[J].Clin Oncol,2013,31():1997-20032
[49] GANDHI L,BAHLEDA R,TOLANEY S M,et al.Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors[J].Clin Oncol,2014,32():68-75.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录